AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8100152 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (FEN)
Number of subjects: 20
Study 8100152 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 20
Study 3312450 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) inhalation aerosol
Number of subjects: 0
Study 3312450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31277720 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 27873451 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ) 337.5 mg/kg per day in three doses, 1-hr DIV, maximum 13.5 g per day
Number of subjects: 105
Study 27873451 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (MEPM) 120 mg/kg per day in three doses, 1-hr DIV, maximum 3 g per day
Number of subjects: 105
Study 26519819 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniArc®
Number of subjects: 44
Study 26519819 — intervention group
Group type: COMPARATOR
Intervention: Monarc™
Number of subjects: 44
Study 24598216 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil with an effect-site target concentration of 3 ng/ml
Number of subjects: 25
Study 24598216 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 25
Study 24598216 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and Saline (placebo)
Number of subjects: 25
Study 22976604 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 79
Study 22976604 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (no-MBP)
Number of subjects: 79
Study 19470037 — intervention group
Group type: EXPERIMENTAL
Intervention: Women receiving ICDs
Number of subjects: 1530
Study 17305698 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with titanium posts
Number of subjects: 183
Study 17305698 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with cast post-and-cores
Number of subjects: 183
Study 17305698 — intervention group
Group type: COMPARATOR
Intervention: Restored without post restorations (control)
Number of subjects: 183
Study 17305698 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 183
Study 15371002 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial compartment osteoarthritic knees
Number of subjects: 18
Study 15371002 — intervention group
Group type: COMPARATOR
Intervention: Healthy knees
Number of subjects: 18
Study 15371002 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene and methacrylate cement
Number of subjects: 18
Study 12182258 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ramosetron 0.15 mg
Number of subjects: 80
Study 12182258 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ramosetron 0.3 mg
Number of subjects: 80
Study 12182258 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ramosetron 0.6 mg
Number of subjects: 80
Study 12182258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10448289 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen (TAM) 20 mg daily for 2 years
Number of subjects: 596
Study 10448289 — intervention group
Group type: COMPARATOR
Intervention: TAM plus one cycle of low-dose, short-term chemotherapy
Number of subjects: 596
Study 10448289 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 mutations within the L2/L3 domains
Number of subjects: 596
Study 10448289 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 mutations in the L2/L3 domains
Number of subjects: 596
Study 8561485 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat butter (41% fat)
Number of subjects: 75
Study 8561485 — intervention group
Group type: COMPARATOR
Intervention: Regular butter (82% fat)
Number of subjects: 75
Study 2651100 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis with absolute alcohol (Asaki's method)
Number of subjects: 145
Study 2651100 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (blood transfusions, antacids, cimetidine, pirenzepine)
Number of subjects: 145
Study 2651100 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 145
Study 373100 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg tienilic acid
Number of subjects: 8
Study 373100 — intervention group
Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide
Number of subjects: 8
Study 30789873 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized 3D-printed AFO
Number of subjects: 60
Study 30789873 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated AFO
Number of subjects: 60
Study 28326653 — intervention group
Group type: EXPERIMENTAL
Intervention: CBASP
Number of subjects: 60
Study 28326653 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC
Number of subjects: 60
Study 25837532 — intervention group
Group type: EXPERIMENTAL
Intervention: 250ppm fluoride dentifrice
Number of subjects: 62
Study 25837532 — intervention group
Group type: EXPERIMENTAL
Intervention: 1150ppm fluoride dentifrice
Number of subjects: 62
Study 25837532 — intervention group
Group type: EXPERIMENTAL
Intervention: 1426ppm fluoride dentifrice
Number of subjects: 62
Study 25837532 — intervention group
Group type: COMPARATOR
Intervention: No fluoride dentifrice
Number of subjects: 62
Study 24849193 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/hydrochlorothiazide (20/12.5 mg) fixed-dose combination tablet
Number of subjects: 41
Study 22999396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400μg
Number of subjects: 366
Study 22999396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study 19939303 — intervention group
Group type: EXPERIMENTAL
Intervention: Being with Dying: Professional Training Program in Contemplative End‐of‐Life Care (BWD)
Number of subjects: 95
Study 17543781 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg everolimus
Number of subjects: 634
Study 17543781 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg everolimus
Number of subjects: 634
Study 17543781 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 634
Study 15480108 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone inhibitor (amiloride and hydrochlorothiazide)
Number of subjects: 90
Study 15480108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15480108 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra amiloride
Number of subjects: 90
Study 11707879 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10200704 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied mesalazine 5%
Number of subjects: 25
Study 10200704 — intervention group
Group type: COMPARATOR
Intervention: Topically applied clobetasol propionate 0.05%
Number of subjects: 25
Study 8311218 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 60
Study 8311218 — intervention group
Group type: COMPARATOR
Intervention: Tegaderm dressing with EMLA cream
Number of subjects: 60
Study 2571116 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 6
Study 2571116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2571116 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 6
Study 2571116 — intervention group
Group type: COMPARATOR
Intervention: Clonidine-desipramine combination
Number of subjects: 6
Study 778302 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, attenuated influenza A/England/42/72 (H3N2) vaccine
Number of subjects: 264
Study 778302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 31173118 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Activation Tool (PAT)
Number of subjects: 200
Study 31173118 — intervention group
Group type: COMPARATOR
Intervention: Standardized consultation
Number of subjects: 200
Study 31173118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 200
Study 31173118 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 200
Study 26318350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular diphtheria-tetanus-pertussis vaccine (at least three doses)
Number of subjects: 936
Study 26318350 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 to Grade 4 students
Number of subjects: 936
Study 26318350 — intervention group
Group type: EXPERIMENTAL
Intervention: Class grades
Number of subjects: 936
Study 26240957 — intervention group
Group type: EXPERIMENTAL
Intervention: Group singing therapy
Number of subjects: 0
Study 26240957 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23396206 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose JX-594
Number of subjects: 30
Study 23396206 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose JX-594
Number of subjects: 30
Study 23396206 — intervention group
Group type: EXPERIMENTAL
Intervention: JX-594
Number of subjects: 30
Study 21446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial lidocaine (20 mg)
Number of subjects: 101
Study 21446376 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 101
Study 21446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial lidocaine
Number of subjects: 101
Study 19540521 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 74
Study 19540521 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 74
Study 19540521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoisocaproate as a probe after RFA
Number of subjects: 74
Study 19540521 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 74
Study 19540521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with HCC
Number of subjects: 74
Study 17679043 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril at 10 mg
Number of subjects: 30
Study 17679043 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol at 100 mg
Number of subjects: 30
Study 17679043 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 15060258 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair)
Number of subjects: 29
Study 15060258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15060258 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 29
Study 11228370 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated measles vaccine (Hu191)
Number of subjects: 503
Study 9553317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (examined three times in each trimester)
Number of subjects: 60
Study 9553317 — intervention group
Group type: EXPERIMENTAL
Intervention: Labored women (examined three times, once in each stage of delivery)
Number of subjects: 60
Study 9553317 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women
Number of subjects: 60
Study 8067495 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-60 mg/day of fluoxetine
Number of subjects: 41
Study 8067495 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day of fluoxetine plus 300-600 mg/day of lithium
Number of subjects: 41
Study 8067495 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day of fluoxetine plus 25-50 mg/day of desipramine
Number of subjects: 41
Study 3072923 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% norfloxacin
Number of subjects: 120
Study 3072923 — intervention group
Group type: COMPARATOR
Intervention: 0.3% tobramycin
Number of subjects: 120
Study 31743177 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 35
Study 31743177 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 35
Study 31743177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum
Number of subjects: 35
Study 31743177 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Number of subjects: 35
Study 31743177 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline to Trendelenburg
Number of subjects: 35
Study 31743177 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery end compared to baseline
Number of subjects: 35
Study 29972593 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed-of-processing training (SOPT)
Number of subjects: 351
Study 29972593 — intervention group
Group type: COMPARATOR
Intervention: Attention control (solving computerized crossword puzzles)
Number of subjects: 351
Study 27782758 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding education and support program
Number of subjects: 100
Study 27782758 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100
Study 25180722 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 104
Study 25180722 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing insulin dose
Number of subjects: 104
Study 25180722 — intervention group
Group type: COMPARATOR
Intervention: Control patients (conventional therapy)
Number of subjects: 104
Study 23271777 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment for clinically localized prostate cancer
Number of subjects: 0
Study 23271777 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 0
Study 19331675 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus Depression Care for People with Cancer
Number of subjects: 500
Study 19331675 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study 17447116 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg once daily for 1 year
Number of subjects: 17
Study 17447116 — intervention group
Group type: COMPARATOR
Intervention: Control (no pharmacotherapy)
Number of subjects: 17
Study 15464332 — intervention group
Group type: EXPERIMENTAL
Intervention: QT variability (QTVN)
Number of subjects: 817
Study 15464332 — intervention group
Group type: EXPERIMENTAL
Intervention: QT variability (QTVI)
Number of subjects: 817
Study 15464332 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curves for QTVN
Number of subjects: 817
Study 15464332 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curves for QTVI
Number of subjects: 817
Study 15464332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression for QTVN
Number of subjects: 817
Study 15464332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression for QTVI
Number of subjects: 817
Study 12269652 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 428
Study 12269652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study 12269652 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 428
Study 9851950 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units, single intravenous infusion)
Number of subjects: 11712
Study 9851950 — intervention group
Group type: COMPARATOR
Intervention: Control (no thrombolytic therapy)
Number of subjects: 11712
Study 7989941 — intervention group
Group type: EXPERIMENTAL
Intervention: 175 mg/m2 of Taxol over 24 hours
Number of subjects: 391
Study 7989941 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mg/m2 of Taxol over 24 hours
Number of subjects: 391
Study 7989941 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol administered as a 3-hour infusion
Number of subjects: 391
Study 7989941 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol administered as a 24-hour infusion
Number of subjects: 391
Study 7989941 — intervention group
Group type: COMPARATOR
Intervention: 24-hour infusion
Number of subjects: 391
Study 2927639 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 90
Study 2927639 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride + low dose levodopa
Number of subjects: 90
Study 2927639 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 90
Study 31623474 — intervention group
Group type: EXPERIMENTAL
Intervention: strain-based ANN model
Number of subjects: 204
Study 31623474 — intervention group
Group type: EXPERIMENTAL
Intervention: full feature ANN model
Number of subjects: 204
Study 31623474 — intervention group
Group type: COMPARATOR
Intervention: full feature logistic regression model
Number of subjects: 204
Study 30633891 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact-resistant lenses
Number of subjects: 114
Study 28007576 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin-EIR (400 mg)
Number of subjects: 60
Study 28007576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26423649 — intervention group
Group type: COMPARATOR
Intervention: Ongoing triple therapy (OT)
Number of subjects: 587
Study 26423649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted protease inhibitor monotherapy (PI-mono)
Number of subjects: 587
Study 23494869 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling to support physical activity (n=106)
Number of subjects: 192
Study 23494869 — intervention group
Group type: COMPARATOR
Intervention: Contact control (n=86)
Number of subjects: 192
Study 23494869 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 150 min/week of PA at both 3 and 6 months
Number of subjects: 192
Study 21712474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 133065
Study 19142802 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 12
Study 19142802 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 12
Study 19142802 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of SA technology and ELISA for IL-8
Number of subjects: 12
Study 17942465 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care program 1
Number of subjects: 0
Study 17942465 — intervention group
Group type: COMPARATOR
Intervention: Antenatal care program 2
Number of subjects: 0
Study 14749158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (150 mg twice daily)
Number of subjects: 594
Study 14749158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study 11257560 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD 0.035 mg/kg (2.5 mg maximum)
Number of subjects: 20
Study 11257560 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD 0.10 mg/kg (7.5 mg maximum)
Number of subjects: 20
Study 11257560 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD (both doses)
Number of subjects: 20
Study 11257560 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD (higher dose)
Number of subjects: 20
Study 11257560 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD co-administration with CsA
Number of subjects: 20
Study 9278800 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvisc
Number of subjects: 100
Study 9278800 — intervention group
Group type: COMPARATOR
Intervention: Healon
Number of subjects: 100
Study 8052810 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam
Number of subjects: 59
Study 8052810 — intervention group
Group type: COMPARATOR
Intervention: cotrimoxazole
Number of subjects: 59
Study 3566234 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 172
Study 3566234 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 172
Study 29741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness training
Number of subjects: 0
Study 29741531 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (control group)
Number of subjects: 0
Study 26612703 — intervention group
Group type: EXPERIMENTAL
Intervention: TrueCPR
Number of subjects: 140
Study 26612703 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR‐Ezy
Number of subjects: 140
Study 26612703 — intervention group
Group type: EXPERIMENTAL
Intervention: iCPR
Number of subjects: 140
Study 26612703 — intervention group
Group type: COMPARATOR
Intervention: Standard BLS
Number of subjects: 140
Study 24029624 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 257
Study 24029624 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 257
Study 23719547 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (600 mg) plus Vitamin D3 (200 IU) supplementation
Number of subjects: 56
Study 23719547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 19449238 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 39
Study 19449238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 18444444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg)
Number of subjects: 27
Study 18444444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (20 mg)
Number of subjects: 27
Study 18444444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16803489 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure (LEEP)
Number of subjects: 60
Study 12768254 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography (MRA)
Number of subjects: 19
Study 12768254 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter angiography (CCA)
Number of subjects: 19
Study 12768254 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MRA and CCA
Number of subjects: 19
Study 11503995 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 60
Study 11503995 — intervention group
Group type: EXPERIMENTAL
Intervention: Super‐EBA
Number of subjects: 60
Study 11503995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin-bonded resin
Number of subjects: 60
Study 11503995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate
Number of subjects: 60
Study 11503995 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 60
Study 11503995 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 60
Study 9169179 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertile women
Number of subjects: 413